OOIR: Observatory of International Research

Papers

(The H4-Index of Endocrine Reviews is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Papillary Craniopharyngioma: An Integrative and Comprehensive Review	473
Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway	275
Endocrine Manifestations and New Developments in Mitochondrial Disease	241
Correction to: “ER Stress in Cardiometabolic Diseases: From Molecular Mechanisms to Therapeutics”	234
Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes	203
Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies	200
LGR4: A New Receptor Member in Endocrine and Metabolic Diseases	178
Coxsackievirus and Type 1 Diabetes: Diabetogenic Mechanisms and Implications for Prevention	175
The Molecular Biology of Midgut Neuroendocrine Neoplasms	172
Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing’s Syndrome	160
The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story	157
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures	136
Correction to: “The Congenital and Acquired Mechanisms Implicated in the Etiology of Central Precocious Puberty”	124
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies	92
Stem Cells and Organs-on-chips: New Promising Technologies for Human Infertility Treatment	88
The Biology and Clinical Implications of PCSK7	86
Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors	86
The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism	76
Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?	75
Current Challenges and Future Directions in the Assessment of Glucocorticoid Status	74
Estrogen Receptor Signaling in the Immune System	74
Post-translational Modifications: The Signals at the Intersection of Exercise, Glucose Uptake, and Insulin Sensitivity	74
Erratum to: “The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens”	72
Contemporary Biological Insights and Clinical Management of Craniopharyngioma	70
New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth Review of the Literature	66

Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas	60
Time-restricted Eating for the Prevention and Management of Metabolic Diseases	60
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance	59
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction	56
The Metabolic Role and Therapeutic Potential of the Microbiome	54
Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review	53
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia	52
Adiponectin and Adiponectin Receptors in Atherosclerosis	52
Subtyping of Primary Aldosteronism by Adrenal Venous Sampling	52
Endotrophin, a Key Marker and Driver for Fibroinflammatory Disease	50
The Cortisol Awakening Response: Regulation and Functional Significance	50
Imaging of Pheochromocytomas and Paragangliomas	49
International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood	48
Molecular and Clinical Spectrum of Primary Hyperparathyroidism	43
Brown Adipose Tissue—A Translational Perspective	41
Hippo Signaling in the Ovary: Emerging Roles in Development, Fertility, and Disease	40
Erratum to: Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment	40
Molecular Developments in Parasellar Tumors and Potential Therapeutic Implications	40